Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07414784 · ClinicalTrials.gov registry record · Phase 1

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT07414784: Recruiting Phase 1 study of Healthy Volunteer, sponsored by AbbVie.

NCT07414784 is a Phase 1 study of Healthy Volunteer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 20 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07414784, a Phase 1 study of Healthy Volunteer, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

Primary Outcome

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Conditions Studied

Interventions

  • DRUG ABBV-295
  • DRUG Levonorgestrel/Ethinyl Estradiol

Study Locations (1)

Illinois

  • ACPRU - Grayslake

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-02-11
Est. Completion 2026-07
Phase Phase 1
AbbVie

526 total trials

What NCT07414784 shows while recruiting

NCT07414784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which ABBV-295 is the first listed.

NCT07414784 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07414784 about?

NCT07414784 is a clinical study titled "A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives". This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

What is the current status of trial NCT07414784?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-11. Estimated completion is 2026-07.

What conditions does trial NCT07414784 study?

This clinical trial studies the following conditions: Healthy Volunteer.

What interventions are being tested in trial NCT07414784?

The interventions under investigation include: ABBV-295 (DRUG), Levonorgestrel/Ethinyl Estradiol (DRUG).

Who is sponsoring clinical trial NCT07414784?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07414784 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07414784's enrollment target sits among peer trials

20 95th of 112 higher than 16 of 112 other Healthy Volunteer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07414784, the US trial registry maintained by the National Library of Medicine. NCT07414784 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.